Fig. 5
From: A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
Time-to-onset of adverse events.
Fig. 5 | Scientific Reports
From: A real-world pharmacovigilance study of Certolizumab pegol based on FAERS database
Time-to-onset of adverse events.
